DescriptionAptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada.
Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.
Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.
A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.
What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.
A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.
Latest Press Releases
|Period||Period Low||Period High||Performance|
|1-Month|| 2.11 +3.87% increase |
| 2.63 -16.73% decrease |
| -0.42 (-16.09%) decrease |
|3-Month|| 2.11 +3.87% increase |
| 3.13 -29.92% decrease |
| -0.64 (-22.61%) decrease |
|52-Week|| 2.11 +3.87% increase |
| 7.27 -69.88% decrease |
| -3.53 (-61.68%) decrease |